Global FSGS Therapeutics Market Projected to Reach USD 4.89 Billion by 2033, Growing at a CAGR of 5%

The global Focal Segmental Glomerulosclerosis (FSGS) therapeutics market is poised for substantial growth, with a projected market value of USD 3 billion in 2023, expected to accumulate to USD 4.89 billion by 2033. This expansion reflects a steady Compound Annual Growth Rate (CAGR) of 5% during the forecast period from 2023 to 2033.

Several factors contribute to this upward trend, including:

1. Rising Incidence of Chronic Kidney Disease: The global increase in chronic kidney disease cases is driving demand for FSGS therapeutics, as FSGS is a common cause of nephrotic syndrome, leading to kidney failure if untreated.
2. Advancements in Drug Development: Ongoing research and development in FSGS treatment, including novel drug formulations, are enhancing treatment options and outcomes for patients.
3. Increased Awareness and Diagnosis Rates: Improved awareness and diagnostic capabilities are enabling earlier identification and intervention for FSGS, leading to better patient care and supporting market growth.
4. Investment in Specialized Therapies: Increased investments in targeted and personalized treatment options are fueling the expansion of the FSGS therapeutics market, providing specialized solutions for this challenging kidney disorder.

Historically, the FSGS therapeutics market registered a CAGR of 3.5% from 2018 to 2022, underscoring the growing need for effective treatments. As the market continues to evolve, stakeholders are encouraged to leverage these growth opportunities and invest in the future of FSGS therapeutics.

Which are Some Prominent Drivers of the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market?

Growing Awareness along with Increasing Prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth

One of the main factors is the increasing prevalence of FSGS worldwide. According to the National Institutes of Health (NIH), FSGS is a rare disease, affecting 7.5 per million people in the United States. However, the incidence of FSGS is increasing, especially in certain ethnic groups, such as African Americans and Hispanics.

In addition to the increasing prevalence of FSGS, advances in research and development are leading to the development of new treatments and therapies for the disease. There are several experimental drugs and therapies being developed for the treatment of FSGS, including monoclonal antibodies, stem cell therapy, and genetic therapies. These new treatments offer hope to patients with FSGS and are expected to contribute to the growth of the market.

Another factor contributing to the growth of the FSGS therapeutics market is increasing awareness and education about the disease. As more information becomes available about FSGS, healthcare providers are better equipped to diagnose and treat the disease. Patients and their families are also becoming more informed about FSGS, which can lead to earlier diagnosis and treatment.

Market Competition

Key players in the market include companies such as Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc along with healthcare providers and technology companies among other global players.

• In May 2022, Travere Therapeutics, Inc. (NASDAQ: TVTX) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan to treat IgA nephropathy (IgAN) and has granted Priority Review. Travere Therapeutics is looking forward to working with the FDA throughout the review process to potentially deliver sparsentan to the IgA nephropathy community.

The NDA submission for sparsentan is based on results from the ongoing Phase 3 PROTECT Study, which is one of the largest interventional studies conducted in IgAN to date. The study evaluated sparsentan in 404 patients with persistent proteinuria and met its pre-specified interim primary efficacy endpoint, which measured changes in proteinuria compared to the active control irbesartan.

Key Companies Profiled

Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc

A Full Report Overview

Key Segments Profiled in the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Industry Survey

Disease Type:

• Primary FSGS
• Secondary FSGS

Drug Class:

• Corticosteroids
• Immunosuppressive Drugs
• Plasmapheresis
• ACE Inhibitors and ARBs
• Diuretics

Treatment:

• Drug Therapy
• Dialysis
• Kidney Transplant

Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube